News coverage about Brainstorm Cell Therapeutics (NASDAQ:BCLI) has trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.6779319245499 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Brainstorm Cell Therapeutics Inc. (BCLI) Expected to Post Earnings of -$0.09 Per Share (americanbankingnews.com)
- Zacks: Brainstorm Cell Therapeutics Inc. (BCLI) Given $12.00 Average Target Price by Analysts (americanbankingnews.com)
- Brainstorm (BCLI) Says Abstracts on Phase 2 NurOwn Biomarkers Accepted for Presentation at International Symposium on ALS/MND (streetinsider.com)
- Brainstorm (BCLI) Says Abstracts on Phase 2 NurOwn Biomarkers … – StreetInsider.com (streetinsider.com)
- BrainStorm’s Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston (finance.yahoo.com)
Brainstorm Cell Therapeutics (NASDAQ:BCLI) traded up $0.02 during mid-day trading on Tuesday, reaching $4.00. The company’s stock had a trading volume of 112,100 shares, compared to its average volume of 134,203. Brainstorm Cell Therapeutics has a one year low of $2.07 and a one year high of $5.18.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period last year, the firm posted ($0.09) EPS. equities analysts expect that Brainstorm Cell Therapeutics will post -0.37 EPS for the current year.
Separately, Maxim Group set a $9.00 price target on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Monday, October 16th.
ILLEGAL ACTIVITY WARNING: This story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2017/12/05/brainstorm-cell-therapeutics-bcli-getting-somewhat-positive-media-coverage-analysis-finds.html.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.